Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection

Frontiers in Microbiology

Volumn 6, Issue JUL, 2015, Pages

  Benedict, Ashwini ^a   Bansal, Neha ^a   Senina, Svetlana ^a   Hooper, Idris ^a   Lundberg, Lindsay ^a   de la Fuente, Cynthia ^a   Narayanan, Aarthi ^a   Gutting, Bradford ^b   Kehn Hall, Kylene ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b NAVAL SURFACE WARFARE CENTER   (United States)

Author keywords

FDA; Raf; Replication; Rift valley fever virus; Sorafenib; Viral egress

Indexed keywords

B RAF KINASE; C RAF KINASE; CURCUMIN; RAF PROTEIN; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL VIABILITY ASSAY; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; EC50; FEMALE; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; TOXICITY; VIRAL PLAQUE ASSAY; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS RELEASE; VIRUS REPLICATION; WESTERN BLOTTING;

RIFT VALLEY FEVER VIRUS;

EID: 84938830575     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00676     Document Type: Article

References (65)

1. Adnane, L., Trail, P. A., Taylor, I., and Wilhelm, S. M. (2006). Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Meth. Enzymol. 407, 597-612. doi: 10.1016/S0076-6879(05)07047-3.
2. Apolloni, S., Fabbrizio, P., Parisi, C., Amadio, S., and Volonté, C. (2014). Clemastine confers neuroprotection and induces an anti-inflammatory phenotype in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Mol. Neurobiol. doi: 10.1007/s12035-014-9019-8. [Epub ahead of print].
3. Arias, A., Arnold, J. J., Sierra, M., Smidansky, E. D., Domingo, E., and Cameron, C. E. (2008). Determinants of RNA-dependent RNA polymerase (In)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J. Virol. 82, 12346-12355. doi: 10.1128/JVI.01297-08.
4. Arndts, K., Klarmann-Schulz, U., Batsa, L., Debrah, A. Y., Epp, C., Fimmers, R., et al. (2015). Reductions in microfilaridermia by repeated ivermectin treatment are associated with lower Plasmodium-specific Th17 immune responses in Onchocerca volvulus-infected individuals. Parasit. Vectors 8, 184. doi: 10.1186/s13071-015-0786-5.
5. Austin, D., Baer, A., Lundberg, L., Shafagati, N., Schoonmaker, A., Narayanan, A., et al. (2012). p53 Activation following rift valley fever virus infection contributes to cell death and viral production. PLoS ONE 7:e36327. doi: 10.1371/journal.pone.0036327.
6. Baer, A., and Kehn-Hall, K. (2014). Viral concentration determination through plaque assays: using traditional and novel overlay systems. J. Vis. Exp. 4:e52065. doi: 10.3791/52065.
7. Beach, L. B., Rawson, J. M., Kim, B., Patterson, S. E., and Mansky, L. M. (2014). Novel inhibitors of human immunodeficiency virus type 2 infectivity. J. Gen. Virol. 95, 2778-2783. doi: 10.1099/vir.0.069864-0.
8. Buchholz, U. J., Finke, S., and Conzelmann, K.-K. (1999). Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251-259.
9. Caroline, A. L., Powell, D. S., Bethel, L. M., Oury, T. D., Reed, D. S., and Hartman, A. L. (2014). Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational rift valley fever. PLoS Negl. Trop. Dis. 8:e2790. doi: 10.1371/journal.pntd.0002790.
10. Chew, W.-S., and Ong, W.-Y. (2014). Regulation of calcium-independent phospholipase A2 expression by adrenoceptors and sterol regulatory element binding protein-potential crosstalk between sterol and glycerophospholipid mediators. Mol. Neurobiol. doi: 10.1007/s12035-014-9026-9. [Epub ahead of print].
11. Chong, Z. Z., and Maiese, K. (2007). The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol. 22, 1251-1267.
12. Chung, B. Y., Kim, S. Y., Jung, J. M., Won, C. H., Choi, J. H., Lee, M. W., et al. (2015). The antimycotic agent clotrimazole inhibits melanogenesis by accelerating ERK and PI3K-/Akt-mediated tyrosinase degradation. Exp. Dermatol. 24, 386-388. doi: 10.1111/exd.12669.
13. Clark, P. I., and Slevin, M. L. (1987). The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12, 223-252. doi: 10.2165/00003088-198712040-00001.
14. Denisova, O. V., Kakkola, L., Feng, L., Stenman, J., Nagaraj, A., Lampe, J., et al. (2012). Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J. Biol. Chem. 287, 35324-35332. doi: 10.1074/jbc.M112.392142.
15. Descamps, V., Helle, F., Louandre, C., Martin, E., Brochot, E., Izquierdo, L., et al. (2015). The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. Antiviral Res. 118, 93-102. doi: 10.1016/j.antiviral.2015.03.012.
16. Feldstein, S., Totri, C., and Friedlander, S. F. (2015). Antifungal therapy for onychomycosis in children. Clin. Dermatol. 33, 333-339. doi: 10.1016/j.clindermatol.2014.12.010.
17. Fischer, M. A., Smith, J. L., Shum, D., Stein, D. A., Parkins, C., Bhinder, B., et al. (2013). Flaviviruses are sensitive to inhibition of thymidine synthesis pathways. J. Virol. 87, 9411-9419. doi: 10.1128/JVI.00101-13.
18. Flaherty, K. T., Schiller, J., Schuchter, L. M., Liu, G., Tuveson, D. A., Redlinger, M., et al. (2008). A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 4836-4842. doi: 10.1158/1078-0432.CCR-07-4123.
19. Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., and Barnard, D. L. (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 100, 446-454. doi: 10.1016/j.antiviral.2013.09.015.
20. Gao, Q., Yuan, S., Zhang, C., Wang, Y., Wang, Y., He, G., et al. (2015). Discovery of Itraconazole with broad-spectrum in vitro anti-enterovirus activity that targets nonstructural protein 3A. Antimicrob. Agents Chemother. 59, 2654-2665. doi: 10.1128/AAC.05108-14.
21. Golnar, A. J., Turell, M. J., LaBeaud, A. D., Kading, R. C., and Hamer, G. L. (2014). Predicting the mosquito species and vertebrate species involved in the theoretical transmission of Rift Valley fever virus in the United States. PLoS Negl. Trop. Dis. 8:e3163. doi: 10.1371/journal.pntd.0003163.
22. Gorbunova, E. E., Gavrilovskaya, I. N., Pepini, T., and Mackow, E. R. (2011). VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J. Virol. 85, 2296-2303. doi: 10.1128/JVI.02319-10.
23. Habjan, M., Penski, N., Spiegel, M., and Weber, F. (2008). T7 RNA polymerase-dependent and-independent systems for cDNA-based rescue of Rift Valley fever virus. J. Gen. Virol. 89, 2157-2166. doi: 10.1099/vir.0.2008/002097-0.
24. Handel, A., Longini, I. M., and Antia, R. (2010). Towards a quantitative understanding of the within-host dynamics of influenza A infections. J. R. Soc. Interface 7, 35-47. doi: 10.1098/rsif.2009.0067.
25. Hariri, W., Sudha, T., Bharali, D. J., Cui, H., and Mousa, S. A. (2015). Nano-Targeted delivery of Toremifene, an Estrogen Receptor-a Blocker in Prostate cancer. Pharm. Res. doi: 10.1007/s11095-015-1662-x. [Epub ahead of print].
26. Harmon, B., Schudel, B. R., Maar, D., Kozina, C., Ikegami, T., Tseng, C.-T. K., et al. (2012). Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis. J. Virol. 86, 12954-12970. doi: 10.1128/JVI.02242-12.
27. Humbert, M., de Blay, F., Garcia, G., Prud'homme, A., Leroyer, C., Magnan, A., et al. (2009). Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 64, 1194-1201. doi: 10.1111/j.1398-9995.2009.02122.x.
28. Ikegami, T. (2012). Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res. 95, 293-310. doi: 10.1016/j.antiviral.2012.06.001.
29. Ikegami, T., and Makino, S. (2011). The pathogenesis of Rift Valley fever. Viruses 3, 493-519. doi: 10.3390/v3050493.
30. Ikegami, T., Won, S., Peters, C. J., and Makino, S. (2006). Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 80, 2933-2940. doi: 10.1128/JVI.80.6.2933-2940.2006.
31. Johansen, L. M., Brannan, J. M., Delos, S. E., Shoemaker, C. J., Stossel, A., Lear, C., et al. (2013). FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med. 5, 190ra79. doi: 10.1126/scitranslmed.3005471.
32. Kalveram, B., Lihoradova, O., Indran, S. V., and Ikegami, T. (2011). Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy. J. Vis. Exp. e3400. doi: 10.3791/3400.
33. Keating, G. M., and Santoro, A. (2009). Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69, 223-240. doi: 10.2165/00003495-200969020-00006.
34. Klemm, C., Reguera, J., Cusack, S., Zielecki, F., Kochs, G., and Weber, F. (2013). Systems to establish bunyavirus genome replication in the absence of transcription. J. Virol. 87, 8205-8212. doi: 10.1128/JVI.00371-13.
35. Lai, A., Kahraman, M., Govek, S., Nagasawa, J., Bonnefous, C., Julien, J., et al. (2015). Identification of GDC-0810 (ARN-810), an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J. Med. Chem. 58, 4888-4904. doi: 10.1021/acs.jmedchem.5b00054.
36. LaPointe, N. E., Morfini, G., Brady, S. T., Feinstein, S. C., Wilson, L., and Jordan, M. A. (2013). Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 37, 231-239. doi: 10.1016/j.neuro.2013.05.008.
37. Lindenbach, B. D., and Rice, C. M. (1997). trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 71, 9608-9617.
38. Liu, C.-Y., Tseng, L.-M., Su, J.-C., Chang, K.-C., Chu, P.-Y., Tai, W.-T., et al. (2013). Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 15, R63. doi: 10.1186/bcr3457.
39. Lundberg, L., Pinkham, C., Baer, A., Amaya, M., Narayanan, A., Wagstaff, K. M., et al. (2013). Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication. Antiviral Res. 100, 662-672. doi: 10.1016/j.antiviral.2013.10.004.
40. Madrid, P. B., Chopra, S., Manger, I. D., Gilfillan, L., Keepers, T. R., Shurtleff, A. C., et al. (2013). A Systematic Screen of FDA-Approved drugs for inhibitors of biological threat agents. PLoS ONE 8:e60579. doi: 10.1371/journal.pone.0060579.
41. McGrail, D. J., Khambhati, N. N., Qi, M. X., Patel, K. S., Ravikumar, N., Brandenburg, C. P., et al. (2015). Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent Manner. Sci. Rep. 5:9529. doi: 10.1038/srep09529.
42. Mizuuchi, H., Suda, K., Sato, K., Tomida, S., Fujita, Y., Kobayashi, Y., et al. (2015). Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. PLoS ONE 10:e0123901. doi: 10.1371/journal.pone.0123901.
43. Narayanan, A., Kehn-Hall, K., Senina, S., Lundberg, L., Van Duyne, R., Guendel, I., et al. (2012). Curcumin inhibits rift valley fever virus replication in human cells. J. Biol. Chem. 287, 33198-33214. doi: 10.1074/jbc.M112.356535.
44. Nicholas, D. E., Jacobsen, K. H., and Waters, N. M. (2014). Risk factors associated with human Rift Valley fever infection: systematic review and meta-analysis. Trop. Med. Int. Health 19, 1420-1429. doi: 10.1111/tmi.12385.
45. Pisu, C., Pira, L., and Pani, L. (2010). Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. Behav. Pharmacol. 21, 649-653. doi: 10.1097/FBP.0b013e32833e7eab.
46. Popova, T. G., Turell, M. J., Espina, V., Kehn-Hall, K., Kidd, J., Narayanan, A., et al. (2010). Reverse-phase phosphoproteome analysis of signaling pathways induced by rift valley fever virus in human small airway epithelial cells. PLoS ONE 5:e13805. doi: 10.1371/journal.pone.0013805.
47. Ravikumar, K., Sridhar, B., Bhujanga Rao, A. K. S., and Pulla Reddy, M. (2011). Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer. Acta Crystallogr. C 67, o29-o32. doi: 10.1107/S0108270110047451.
48. Rizos, C. V., and Elisaf, M. S. (2014). Antihypertensive drugs and glucose metabolism. World J. Cardiol. 6, 517-530. doi: 10.4330/wjc.v6.i7.517.
49. Roberts, K. L., Manicassamy, B., and Lamb, R. A. (2015). Influenza A virus uses intercellular connections to spread to neighboring cells. J. Virol. 89, 1537-1549. doi: 10.1128/JVI.03306-14.
50. Roberts, P. J., and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310. doi: 10.1038/sj.onc.1210422.
51. Rolin, A. I., Berrang-Ford, L., and Kulkarni, M. A. (2013). The risk of Rift Valley fever virus introduction and establishment in the United States and European Union. Emerg. Microbes Infect. 2:e81. doi: 10.1038/emi.2013.81.
52. Sai, S., Wakai, T., Vares, G., Yamada, S., Kamijo, T., Kamada, T., et al. (2015). Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo. Oncotarget 6, 5517-5535.
53. Samaee, S.-M. (2015). Experimental assessment of the efficacy of five veterinary broad-spectrum anthelmintics to control the intestinal capillariasis in Zebrafish (Danio rerio). Zebrafish. 12, 255-267. doi: 10.1089/zeb.2014.1043.
54. Shafagati, N., Narayanan, A., Baer, A., Fite, K., Pinkham, C., Bailey, C., et al. (2013). The use of nanotrap particles as a sample enrichment method to enhance the detection of rift valley fever virus. PLoS Negl. Trop. Dis. 7:e2296. doi: 10.1371/journal.pntd.0002296.
55. Treiber, D. K., and Shah, N. P. (2013). Ins and outs of kinase dfg motifs. Chem. Biol. 20, 745-746. doi: 10.1016/j.chembiol.2013.06.001.
56. Vivian, D., and Polli, J. E. (2014). Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. Int. J. Pharm. 475, 597-604. doi: 10.1016/j.ijpharm.2014.09.014.
57. Vogel, V. G. (2015). Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med 13:63. doi: 10.1186/s12916-015-0300-0.
58. Wang, C.-T., Lin, C.-S., Shiau, C.-W., Chu, P.-Y., Hsiao, C.-C., Chiang, Y.-L., et al. (2013). SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells. J. Orthop. Res. 31, 335-342. doi: 10.1002/jor.22218.
59. Welsh, S. J., and Fife, K. (2015). Pazopanib for the treatment of renal cell carcinoma. Future Oncol. 11, 1169-1179. doi: 10.2217/fon.14.274.
60. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844. doi: 10.1038/nrd2130.
61. Xu, L., Gao, H., Huang, J., Wang, H., Zhou, Z., Zhang, Y., et al. (2015). Antiviral therapy improves survival of patients with hepatitis B virus-related hepatocellular carcinoma who treated with sorafenib. J. Gastroenterol. Hepatol. 30, 1032-1039. doi: 10.1111/jgh.12910.
62. Yang, F., Meter, T. E. V., Buettner, R., Hedvat, M., Liang, W., Kowolik, C. M., et al. (2008). Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol. Cancer Ther. 7, 3519-3526. doi: 10.1158/1535-7163.MCT-08-0138.
63. Zerbe, L. K., Dwyer-Nield, L. D., Fritz, J. M., Redente, E. F., Shroyer, R. J., Conklin, E., et al. (2008). Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother. Pharmacol. 62, 605-620. doi: 10.1007/s00280-007-0644-z.
64. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67-73. doi: 10.1177/108705719900400206.
65. Zheng, K., Chen, M., Xiang, Y., Ma, K., Jin, F., Wang, X., et al. (2014). Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB. Biochem. Biophys. Res. Commun. 446, 990-996. doi: 10.1016/j.bbrc.2014.03.050.